Lancet Gastroenterology & Hepatology

Article	Citations
Liver injury in COVID-19: management and challenges	1318
Prolonged presence of SARS-CoV-2 viral RNA in faecal samples	1254
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis	744
Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible?	584
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis	583
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis	465
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation stu	404
SARS-CoV-2 in wastewater: potential health risk, but also data source	375
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis	355
COVID-19 and the liver: little cause for concern	318
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-labe	297
Effect of a deep-learning computer-aided detection system on adenoma detection during colonoscopy (CADe-DB trial): a double-blind randomised study	267
Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis	254
Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study	248
Early detection of pancreatic cancer	246
Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study	235
Implications of COVID-19 for patients with pre-existing digestive diseases	235
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis	230
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease St	223
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study	221
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach	204
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, pha	202
COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy	195
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	194
Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study	186

The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection	184
Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	167
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	147
Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder	144
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study	144
Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden	140
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis	137
Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial	135
Probiotics and COVID-19: one size does not fit all	132
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis	131
Global multi-stakeholder endorsement of the MAFLD definition	128
Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study	121
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement	119
Redefining fatty liver disease: an international patient perspective	119
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	117
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial	116
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis	114
Enteric involvement in hospitalised patients with COVID-19 outside Wuhan	114
Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis	111
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, par	109
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial	108
Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial	105
Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis	105
Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel	104
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement	103
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial	102
Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa	99
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis	99
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	98
Ultra-processed foods and human health: from epidemiological evidence to mechanistic insights	98
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease	98
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial	97
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study	96
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver dise	96
Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study	95
Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis	89
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial	88
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study	88
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomi	87
Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens	85
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority st	85
Preoperative oral antibiotics and surgical-site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial	82
Determining risk factors for mortality in liver transplant patients with COVID-19	82
Global prevalence of hepatitis C virus in children in 2018: a modelling study	80
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial	79
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial	79
Current and emerging therapies for advanced biliary tract cancers	78
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study	77
Gastrointestinal sequelae 90 days after discharge for COVID-19	77
Obesity: another ongoing pandemic	76

Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group	75
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study	74
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial	72
Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement	72
Risk of colorectal cancer incidence and mortality after polypectomy: a Swedish record-linkage study	72
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm,	71
Implications of gastrointestinal manifestations of COVID-19	71
Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China	71
Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines	70
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period	69
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium	69
COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry	67
The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017	67
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis	67
Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis	66
Breaking the therapeutic ceiling in drug development in ulcerative colitis	65
Computer-aided detection versus advanced imaging for detection of colorectal neoplasia: a systematic review and network meta-analysis	64
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial	64
Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial	62
Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad	61
Global reporting of progress towards elimination of hepatitis B and hepatitis C	61
Drinking alone: COVID-19, lockdown, and alcohol-related harm	60
The knowns and unknowns of treatment for alcoholic hepatitis	60
Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey	59
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study	59
Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis	58
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	57
Green endoscopy: a call for sustainability in the midst of COVID-19	57
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial	57
Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial	56
The effect of sleep on gastrointestinal functioning in common digestive diseases	56
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review	55
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases	54
The overlap between irritable bowel syndrome and organic gastrointestinal diseases	54
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial	54
Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis	53
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial	52
Inflammation and malnutrition in inflammatory bowel disease	51
Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis	50
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised tr	50
The impact of COVID-19 on hepatitis elimination	50
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	50
Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification	49
The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study	49
Liver transplantation in patients with alcohol-related liver disease: current status and future directions	49
Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass	49
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial	48
Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study	47
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study	47
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by	46
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question	46
Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study	46
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	46
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study	45
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial	45
The intestinal barrier in disorders of the central nervous system	45
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials	44
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a populat	43
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	43
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial	42
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled,	42
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium	42
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial	42
Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis	42
Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial	41
Drug-induced liver injury in older people	41
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	41
Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis	41
Diversity in clinical trials: an opportunity and imperative for community engagement	41
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial	40
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	40
Prevention and treatment of nutritional complications after bariatric surgery	39
Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a	39
Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health	39
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	39
Stigma and irritable bowel syndrome: a taboo subject?	39
Predicting endoscopic activity recovery in England after COVID-19: a national analysis	38
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis	38
Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial	37
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (O	36

Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials	36
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial	35
Sleep and liver disease: a bidirectional relationship	35
The role of mucins in gastrointestinal barrier function during health and disease	35
Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework	35
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial	34
Roles of the gut virome and mycobiome in faecal microbiota transplantation	34
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study	34
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study	34
One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial	34
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study	34
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	33
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial	33
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroentero	33
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus	32
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic	32
Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak	32
Redefining non-alcoholic fatty liver disease: what's in a name?	32
Small molecule oral targeted therapies in ulcerative colitis	31
Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-	31
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)	31
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	31
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease	31
Diabetes following acute pancreatitis	31
Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective	31
Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia	31
Probiotics and COVID-19	30
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomis	30
Colorectal cancer screening in the USA in the wake of COVID-19	30
Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial	30
Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial	29
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis	29
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study	28
Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward	28
Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group	28
Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models	28
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study	27
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission	27
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	27
The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease	27
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study	26
Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study	26
Global hepatitis C elimination: an investment framework	26
A model of the economic benefits of global hepatitis C elimination: an investment case	26
The phases of hepatitis C elimination: achieving WHO elimination targets	26
Increasing burden of colorectal cancer in China	26
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative	25
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study	25
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma	25
Fully automated magnetically controlled capsule endoscopy for examination of the stomach and small bowel: a prospective, feasibility, two-centre study	25
Resuming liver transplantation amid the COVID-19 pandemic	25
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial	25
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study	25
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas	25
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study	24
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicent	24
The relationship between gastrointestinal cancers and the microbiota	24
Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study	24
Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial	24
Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial	23
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial	23
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	23
Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial	23
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial	23
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?	23
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase	23
Pancreatic cancer: a state of emergency?	23
Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa	23
Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial	22
Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analy	21
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	21
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis	21
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial	21
Faecal immunochemical testing in the COVID-19 era: balancing risk and costs	20
Anal cancer and precancerous lesions: a call for improvement	20
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	20
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study	20
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial	20
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	20
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis	20
USPSTF recommends expansion of colorectal cancer screening	19
Update on the mesentery: structure, function, and role in disease	19
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial	19
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis	19
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia: 5-year follow-up of a randomised controlled trial	19
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial	19
Effect of the COVID-19 pandemic on viral hepatitis services in sub-Saharan Africa	19
Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials	18
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of	18
Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis	18
Probiotics and COVID-19	18
Fatty change of the pancreas: the Pandora's box of pancreatology	18
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system	18
Resuming liver transplantation amid the COVID-19 pandemic	17
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver	17